Gilbert & Cook Inc. Reduces Stock Position in Agilent Technologies, Inc. (NYSE:A)

Gilbert & Cook Inc. trimmed its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 21.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,228 shares of the medical research company’s stock after selling 603 shares during the period. Gilbert & Cook Inc.’s holdings in Agilent Technologies were worth $289,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Crewe Advisors LLC grew its stake in shares of Agilent Technologies by 114.8% during the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 101 shares during the period. Livelsberger Financial Advisory purchased a new stake in Agilent Technologies during the fourth quarter valued at approximately $26,000. VisionPoint Advisory Group LLC bought a new position in Agilent Technologies in the fourth quarter worth approximately $29,000. Ridgewood Investments LLC purchased a new position in shares of Agilent Technologies during the 2nd quarter worth $29,000. Finally, Rise Advisors LLC grew its position in shares of Agilent Technologies by 527.8% during the 1st quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 190 shares during the period.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $142.92 on Tuesday. Agilent Technologies, Inc. has a 52-week low of $96.80 and a 52-week high of $155.35. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. The firm’s fifty day moving average is $135.13 and its 200 day moving average is $138.99. The company has a market cap of $41.70 billion, a price-to-earnings ratio of 33.79, a PEG ratio of 6.63 and a beta of 1.05.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.06. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The business’s revenue was down 5.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.43 EPS. Sell-side analysts forecast that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $140.00, for a total value of $274,120.00. Following the completion of the transaction, the chief executive officer now owns 26,076 shares in the company, valued at approximately $3,650,640. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, SVP Dominique Grau sold 15,000 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the transaction, the senior vice president now directly owns 49,486 shares in the company, valued at approximately $6,595,494.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $140.00, for a total transaction of $274,120.00. Following the completion of the sale, the chief executive officer now directly owns 26,076 shares of the company’s stock, valued at approximately $3,650,640. The disclosure for this sale can be found here. Insiders have sold a total of 18,916 shares of company stock worth $2,557,230 over the last ninety days.

Analysts Set New Price Targets

A has been the topic of a number of recent research reports. Citigroup raised their target price on Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. UBS Group lifted their price objective on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Bank of America boosted their price objective on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. Jefferies Financial Group restated a “hold” rating and set a $135.00 target price (down previously from $152.00) on shares of Agilent Technologies in a research note on Monday, June 3rd. Finally, Wolfe Research lowered shares of Agilent Technologies from an “outperform” rating to a “peer perform” rating in a research report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $141.60.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.